The consortium project "European Patients‘ Academy on Therapeutic Innovation" (EUPATI), funded by the Innovative Medicines Initiative, will provide scientifically reliable, objective, comprehensive information to patients on medicines research and development. It will increase the capacities and capabilities of well-informed patients and patient organisations to be effective ![]()
![]()
![]()
advocates and advisors in medicines research, e.g. in clinical trials, with regulatory authorities and in ethics committees. More about the Patients' Academy
Within your activities as a health professional, patient advocate or researcher, we are sure you have come across interesting educational material on medicines research & development. We do not want to re-invent the wheel. The Patients' Academy is now asking for your help to identify existing educational material and training resources on medicines development. Please go to http://www.patientsacademy.eu/suggest and point us to pre-existing educational material that you found interesting!
The European Patients' Academy on Therapeutic Innovation (EUPATI) was successfully launched on 27 March 2012 during the DIA EuroMeeting in Copenhagen. Over the next five years, this innovative patient-led academy will lead an ambitious project to develop educational material, training courses and a public Internet library to educate patient representatives and the lay public about all processes involved in medicines development.
The Innovative Medicines Initiative (IMI), a public private partnership between the European Commission and EFPIA, funds the 'European Patients' Academy on Therapeutic Innovation' (EUPATI). Starting on 1 February 2012, the patient-led academy will develop educational material, training courses and a public Internet library to educate patient representatives and the lay public about all processes involved in medicines development. Topics will include personalised and predictive medicine, design and conduct of clinical trials, drug safety and risk/benefit assessment, pharmaco-economics as well as patient involvement in drug development. EUPATI will provide educational material in six European languages targeting eleven European countries.